PDT Partners LLC Increases Holdings in DaVita Inc. (NYSE:DVA)

PDT Partners LLC raised its stake in DaVita Inc. (NYSE:DVA) by 25.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 26,887 shares of the company’s stock after acquiring an additional 5,506 shares during the quarter. PDT Partners LLC’s holdings in DaVita were worth $4,408,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of DVA. Verition Fund Management LLC lifted its position in DaVita by 313.6% during the 3rd quarter. Verition Fund Management LLC now owns 9,603 shares of the company’s stock worth $1,574,000 after acquiring an additional 7,281 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of DaVita by 16.6% during the third quarter. Captrust Financial Advisors now owns 3,992 shares of the company’s stock valued at $654,000 after purchasing an additional 569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of DaVita by 22.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 114,166 shares of the company’s stock valued at $18,715,000 after purchasing an additional 20,782 shares during the period. CreativeOne Wealth LLC lifted its position in shares of DaVita by 12.3% during the third quarter. CreativeOne Wealth LLC now owns 3,314 shares of the company’s stock worth $543,000 after purchasing an additional 363 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its stake in shares of DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after purchasing an additional 108,446 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 0.6 %

NYSE:DVA opened at $166.57 on Friday. The stock has a 50-day simple moving average of $158.52 and a 200 day simple moving average of $149.10. DaVita Inc. has a one year low of $99.18 and a one year high of $169.51. The company has a market capitalization of $13.66 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 0.93 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.85 EPS. Sell-side analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, UBS Group upped their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, DaVita presently has a consensus rating of “Hold” and an average target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.